Progress in therapeutic antisense applications for neuromuscular disorders
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Progress in therapeutic antisense applications for neuromuscular disorders
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HUMAN GENETICS
Volume 18, Issue 2, Pages 146-153
Publisher
Springer Nature
Online
2009-10-07
DOI
10.1038/ejhg.2009.160
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dystrophia myotonia: why focus on foci?
- (2009) R P Junghans EUROPEAN JOURNAL OF HUMAN GENETICS
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations
- (2009) Annemieke Aartsma-Rus et al. HUMAN MUTATION
- In vivocomparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
- (2009) Hans A. Heemskerk et al. JOURNAL OF GENE MEDICINE
- Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible?
- (2009) SteveD Wilton et al. NEUROLOGY INDIA
- Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA
- (2009) T. M. Wheeler et al. SCIENCE
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?
- (2008) E RAYBURN et al. DRUG DISCOVERY TODAY
- Doxycycline-controlled splicing modulation by regulated antisense U7 snRNA expression cassettes
- (2008) J Marquis et al. GENE THERAPY
- Manufacturing and characterizing AAV-based vectors for use in clinical studies
- (2008) J F Wright GENE THERAPY
- Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
- (2008) A K Zaiss et al. GENE THERAPY
- Long-Term Benefit of Adeno-Associated Virus/Antisense-Mediated Exon Skipping in Dystrophic Mice
- (2008) Michela Alessandra Denti et al. HUMAN GENE THERAPY
- Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation
- (2008) Kathrin Meyer et al. HUMAN MOLECULAR GENETICS
- Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function
- (2008) HaiFang Yin et al. HUMAN MOLECULAR GENETICS
- Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping
- (2008) Heidi R. Madden et al. HUMAN MUTATION
- By-passing the nonsense mutation in the 4CVmouse model of muscular dystrophy by induced exon skipping
- (2008) Chalermchai Mitrpant et al. JOURNAL OF GENE MEDICINE
- Disability and survival in Duchenne muscular dystrophy
- (2008) M Kohler et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice
- (2008) Natee Jearawiriyapaisarn et al. MOLECULAR THERAPY
- In vivo delivery of naked antisense oligos in aged mdx mice: Analysis of dystrophin restoration in skeletal and cardiac muscle
- (2008) Libero Vitiello et al. NEUROMUSCULAR DISORDERS
- 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: “Planning Phase I/II Clinical trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy”
- (2008) Francesco Muntoni et al. NEUROMUSCULAR DISORDERS
- DMDpseudoexon mutations: splicing efficiency, phenotype, and potential therapy
- (2007) Olga L. Gurvich et al. ANNALS OF NEUROLOGY
- Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides
- (2007) Carmen Bertoni Frontiers in Bioscience-Landmark
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started